WHO ICTRP trial
A Phase 3, Double-Blind Study of TAK-438 (20 mg) in the Treatment of Gastric…
JPRN-jRCT2080221572 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080221572 |
|---|---|
| Public title | A Phase 3, Double-Blind Study of TAK-438 (20 mg) in the Treatment of Gastric Ulcer |
| Scientific title | A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg comparing with AG-1749 in Patients with Gastric Ulcer. |
| Primary sponsor | TAKEDA PHARMACEUTICAL COMPANY LTD. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Gastric Ulcer |
| Interventions | investigational material(s) Generic name etc : TAK-438 INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : 20 mg/day control material(s) Generic… |
| Registration date | Jul 9, 2011 |
| Target size | 482 |
| Secondary IDs | JapicCTI-111612 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: